126.08
price down icon0.66%   -0.84
after-market Dopo l'orario di chiusura: 126.00 -0.08 -0.06%
loading
Precedente Chiudi:
$126.92
Aprire:
$127.2
Volume 24 ore:
1.09M
Relative Volume:
0.67
Capitalizzazione di mercato:
$19.85B
Reddito:
$9.82B
Utile/perdita netta:
$1.48B
Rapporto P/E:
12.45
EPS:
10.13
Flusso di cassa netto:
$2.30B
1 W Prestazione:
-0.76%
1M Prestazione:
-1.80%
6M Prestazione:
-16.67%
1 anno Prestazione:
-44.88%
Intervallo 1D:
Value
$125.60
$128.25
Intervallo di 1 settimana:
Value
$123.21
$129.27
Portata 52W:
Value
$110.03
$238.00

Biogen Inc Stock (BIIB) Company Profile

Name
Nome
Biogen Inc
Name
Telefono
(781) 464-2000
Name
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Name
Dipendente
7,605
Name
Cinguettio
@biogen
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
BIIB's Discussions on Twitter

Confronta BIIB con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
BIIB
Biogen Inc
126.08 19.85B 9.82B 1.48B 2.30B 10.13
Drug Manufacturers - General icon
LLY
Lilly Eli Co
775.45 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
152.41 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
68.51 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
182.31 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
120.01 234.21B 53.22B 12.86B 14.85B 6.39

Biogen Inc Stock (BIIB) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-28 Downgrade HSBC Securities Buy → Hold
2025-04-04 Downgrade Argus Buy → Hold
2025-02-11 Iniziato Bernstein Mkt Perform
2025-01-02 Downgrade Piper Sandler Overweight → Neutral
2024-12-20 Downgrade BMO Capital Markets Outperform → Market Perform
2024-12-16 Downgrade Stifel Buy → Hold
2024-12-10 Ripresa BofA Securities Neutral
2024-12-09 Downgrade Jefferies Buy → Hold
2024-11-18 Downgrade Needham Buy → Hold
2024-11-15 Iniziato Wolfe Research Peer Perform
2024-11-14 Iniziato Citigroup Neutral
2024-10-31 Downgrade Morgan Stanley Overweight → Equal-Weight
2024-10-10 Ripresa Raymond James Mkt Perform
2024-02-14 Reiterato Needham Buy
2024-02-14 Downgrade Wells Fargo Overweight → Equal Weight
2024-01-24 Downgrade UBS Buy → Neutral
2023-12-20 Ripresa Cantor Fitzgerald Overweight
2023-12-07 Aggiornamento Raymond James Mkt Perform → Outperform
2023-09-06 Iniziato HSBC Securities Buy
2023-07-27 Iniziato Scotiabank Sector Outperform
2023-07-24 Reiterato UBS Buy
2023-05-01 Aggiornamento Guggenheim Neutral → Buy
2023-04-17 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-26 Aggiornamento Goldman Neutral → Buy
2022-10-13 Aggiornamento Stifel Hold → Buy
2022-10-07 Aggiornamento Argus Hold → Buy
2022-09-28 Aggiornamento BMO Capital Markets Market Perform → Outperform
2022-09-28 Aggiornamento Mizuho Neutral → Buy
2022-09-28 Aggiornamento Robert W. Baird Neutral → Outperform
2022-04-18 Aggiornamento Wells Fargo Equal Weight → Overweight
2022-03-08 Downgrade Stifel Buy → Hold
2022-03-03 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2022-02-04 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-04 Reiterato Barclays Equal Weight
2022-02-04 Reiterato BofA Securities Neutral
2022-02-04 Reiterato Cowen Outperform
2022-02-04 Reiterato Morgan Stanley Overweight
2022-02-04 Reiterato Needham Buy
2022-02-04 Reiterato Oppenheimer Outperform
2022-02-04 Reiterato RBC Capital Mkts Sector Perform
2022-02-04 Reiterato Robert W. Baird Neutral
2022-02-04 Reiterato Wedbush Neutral
2022-02-04 Reiterato Wells Fargo Equal Weight
2022-02-04 Reiterato Wolfe Research Peer Perform
2022-01-13 Downgrade Guggenheim Buy → Neutral
2022-01-12 Downgrade Piper Sandler Overweight → Neutral
2021-12-10 Ripresa Raymond James Mkt Perform
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-09-23 Iniziato Needham Buy
2021-06-18 Aggiornamento Piper Sandler Neutral → Overweight
2021-06-14 Reiterato Truist Buy
2021-06-11 Aggiornamento Bernstein Mkt Perform → Outperform
2021-06-10 Aggiornamento UBS Neutral → Buy
2021-06-08 Aggiornamento Atlantic Equities Underweight → Neutral
2021-06-08 Reiterato Barclays Equal Weight
2021-06-08 Aggiornamento Citigroup Sell → Neutral
2021-06-08 Reiterato H.C. Wainwright Buy
2021-06-08 Reiterato Jefferies Buy
2021-06-08 Reiterato Morgan Stanley Overweight
2021-06-08 Reiterato RBC Capital Mkts Sector Perform
2021-06-08 Aggiornamento Robert W. Baird Underperform → Neutral
2021-06-08 Reiterato Stifel Buy
2021-06-08 Aggiornamento William Blair Mkt Perform → Outperform
2021-06-07 Aggiornamento BofA Securities Underperform → Neutral
2021-06-07 Aggiornamento Cowen Market Perform → Outperform
2021-06-07 Aggiornamento Raymond James Underperform → Mkt Perform
2021-02-05 Downgrade DZ Bank Buy → Hold
2021-01-29 Aggiornamento Stifel Hold → Buy
2020-11-10 Aggiornamento DZ Bank Hold → Buy
2020-11-09 Downgrade Atlantic Equities Neutral → Underweight
2020-11-09 Downgrade BofA Securities Neutral → Underperform
2020-11-09 Downgrade Cowen Outperform → Market Perform
2020-11-09 Reiterato H.C. Wainwright Buy
2020-11-04 Aggiornamento BofA Securities Underperform → Neutral
2020-11-04 Aggiornamento Jefferies Hold → Buy
2020-11-04 Aggiornamento Wells Fargo Equal Weight → Overweight
2020-10-28 Iniziato UBS Neutral
2020-07-27 Aggiornamento Morgan Stanley Underweight → Overweight
2020-06-22 Downgrade Barclays Overweight → Equal Weight
2020-06-22 Reiterato RBC Capital Mkts Sector Perform
2020-06-09 Downgrade Bernstein Outperform → Mkt Perform
2020-04-23 Downgrade Citigroup Neutral → Sell
2020-04-23 Downgrade Raymond James Mkt Perform → Underperform
2020-03-31 Iniziato Wolfe Research Peer Perform
2020-02-27 Iniziato Barclays Overweight
2020-01-27 Aggiornamento Canaccord Genuity Hold → Buy
2019-12-13 Aggiornamento Credit Suisse Underperform → Neutral
2019-12-02 Downgrade Robert W. Baird Neutral → Underperform
Mostra tutto

Biogen Inc Borsa (BIIB) Ultime notizie

pulisher
Jun 18, 2025

Missouri Trust & Investment Co Has $866,000 Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla - insights.citeline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Grimes & Company Inc. Purchases 33,721 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Fifth Third Bancorp Has $751,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen bids to extend use of Skyclarys to younger patients - pharmaphorum

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Dips on Its Part in BRAVE Study - Baystreet.ca

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen (BIIB) Launches Global Phase 3 BRAVE Study for Omaveloxol - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia | BIIB Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen initiates phase 3 trial of omaveloxolone for children with FA - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - Biogen

Jun 18, 2025
pulisher
Jun 18, 2025

How the Neuroprotection Therapeutics Market Will Evolve by 2032 - openPR.com

Jun 18, 2025
pulisher
Jun 17, 2025

Harbor Capital Advisors Inc. Takes Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly - simplywall.st

Jun 17, 2025
pulisher
Jun 17, 2025

Cutaneous Lupus Erythematosus Market Research Report 2025-2035, Competitive Analysis of Biogen, Bristol-Myers Squibb, Sanofi, AstraZeneca, Gilead Sciences, and Kyowa KirinResearchAndMarkets.com - Bluefield Daily Telegraph

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen patents new HTT splicing modulators - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Eyes Contingent Value in Sage Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bill Nye joins fireside chat supporting Biogen’s Cannes Lion-winning work - Medical Marketing and Media

Jun 17, 2025
pulisher
Jun 16, 2025

NorthCrest Asset Manangement LLC Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus makes depression drug play with $795m Sage buyout - Pharmaceutical Technology

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Biogen (BIIB) Gains from Supernus-Sage Therapeutics Acquisition | BIIB Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals To Acquire Sage Therapeutics - citybiz

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire

Jun 16, 2025
pulisher
Jun 15, 2025

Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

Biogen's (BIIB) "Neutral" Rating Reaffirmed at Piper Sandler - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Pallas Capital Advisors LLC Purchases 7,694 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals

Jun 13, 2025
pulisher
Jun 13, 2025

Neuroregeneration Therapy Market Know the Scope and Trends | - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

Data at EULAR back Biogen, UCB's first-in-class lupus drug - pharmaphorum

Jun 13, 2025
pulisher
Jun 12, 2025

Biogen Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandle - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating and Price Target Reiterated by Piper Sandler Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 ResultsBiogen (NASDAQ:BIIB) - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Earns Neutral Rating from Wedbush - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Receives Neutral Rating With Price Target Maintained | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen: positive Phase 3 data in lupus - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (NASDAQ:BIIB) Receives Hold Rating from Needham & Company LLC - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Demystifying Biogen: Insights From 11 Analyst Reviews - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Global Tardive Dyskinesia Treatment Market 2025 | - openPR.com

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus D - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Rating Reiterated as Hold by Needham Analyst | BIIB Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Biogen (BIIB) Shares Promising Phase 3 Study Results for Lupus Drug Candidate | BIIB Stock News - GuruFocus

Jun 12, 2025

Biogen Inc Azioni (BIIB) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general SNY
$47.85
price down icon 1.08%
$110.67
price up icon 2.83%
drug_manufacturers_general PFE
$24.19
price down icon 0.21%
$277.13
price down icon 0.71%
drug_manufacturers_general MRK
$79.10
price up icon 0.34%
drug_manufacturers_general NVS
$120.01
price down icon 0.26%
Capitalizzazione:     |  Volume (24 ore):